The Biospecimen Core (BC) will provide essential services related to pathology for all projects of this Specialized Program of Research Excellence (SPORE). Each of the three sites (RPCI, UPCI, and Fred Hutchinson Cancer Research Center) in this SPORE will provide local services that are applicable to the project at the particular site. In addition to developing a high quality biospecimen bank, the BC will provide many other services to the SPORE investigators that include tissue microarrays, laser capture microdissection, general research histology services, immunohistochemistry, digital imaging, and pathology review of slides and images. In addition to services directly related to collection or processing of tissues, the BC will also be instrumental in testing of specimens for various markers to determine patient eligibility for the different clinical trials. The BC will directly add to the science of this ovarian SPORE by a detailed immunological annotation of ovarian tumors and the microenvironment.
The BC is instrumental in both the basic and translational research of this ovarian SPORE. Studies performed in the BC will determine patient eligibility for clinical trials that will impact patient care. In addition, the high quality biospecimens provided through the BC will impact the basic research of this ovarian SPORE.
|Gil, Margaret; Komorowski, Marcin P; Seshadri, Mukund et al. (2014) CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. J Immunol 193:5327-37|
|Eng, Kevin H; Ruggeri, Christina (2014) Connecting prognostic ligand receptor signaling loops in advanced ovarian cancer. PLoS One 9:e107193|
|Liao, Jianqun; Qian, Feng; Tchabo, Nana et al. (2014) Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PLoS One 9:e84941|
|Suryawanshi, Swati; Huang, Xin; Elishaev, Esther et al. (2014) Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res 20:6163-74|
|Matsuzaki, Junko; Tsuji, Takemasa; Luescher, Immanuel et al. (2014) Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells. Cancer Immunol Res 2:341-50|
|Daudi, Sayeema; Eng, Kevin H; Mhawech-Fauceglia, Paulette et al. (2014) Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS One 9:e104099|